Andrea Janikova
Overview
Explore the profile of Andrea Janikova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navrkalova V, Mareckova A, Porc J, Hricko S, Hrabcakova V, Kissova J, et al.
Diagn Pathol
. 2025 Feb;
20(1):14.
PMID: 39905397
High-grade B-cell lymphomas (HGBCLs) are aggressive blood cancers with a severe disease course, especially when the central nervous system (CNS) is involved. Standard histological examination depends on tissue availability and...
2.
Villa M, Sharma G, Malighetti F, Mauri M, Arosio G, Cordani N, et al.
Br J Cancer
. 2024 Oct;
131(11):1781-1795.
PMID: 39478125
Background: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene....
3.
Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, et al.
Ann Hematol
. 2024 Oct;
104(1):675-684.
PMID: 39352469
Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of...
4.
Sykorova A, Folber F, Polgarova K, Mocikova H, Duras J, Steinerova K, et al.
Cancer Med
. 2024 Sep;
13(17):e70138.
PMID: 39248284
Aim: The aim of this study was to analyse the outcomes of patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CAR-Tx), with a focus on...
5.
Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, et al.
J Clin Oncol
. 2024 Aug;
42(34):4071-4083.
PMID: 39159403
Purpose: The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. Methods: The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can...
6.
Chamradova K, Batalik L, Winnige P, Dosbaba F, Hartman M, Batalikova K, et al.
Cardiooncology
. 2024 Jul;
10(1):46.
PMID: 39080734
Background: Participation in cardio-oncological rehabilitation is low, and the effects incline to decrease after the initial rehabilitation term. Home-based exercise has the potential to enhance involvement in cardio-oncology rehabilitation and...
7.
Effect of exercise-based cancer rehabilitation via telehealth: a systematic review and meta-analysis
Batalik L, Chamradova K, Winnige P, Dosbaba F, Batalikova K, Vlazna D, et al.
BMC Cancer
. 2024 May;
24(1):600.
PMID: 38760805
Purpose: Exercise-based cancer rehabilitation via digital technologies can provide a promising alternative to centre-based exercise training, but data for cancer patients and survivors are limited. We conducted a meta-analysis examining...
8.
Filakova K, Janikova A, Felsoci M, Dosbaba F, Su J, Pepera G, et al.
BMC Sports Sci Med Rehabil
. 2023 Mar;
15(1):38.
PMID: 36959613
Purpose: Cardiovascular disease is a competing mortality cause in hematological cancer survivors due to toxic oncological treatment, accumulation of risk factors, and decline of cardiorespiratory fitness. Cardio-oncology rehabilitation (CORE) is...
9.
Sykorova A, Prochazka V, Mocikova H, Janikova A, Pytlik R, Belada D, et al.
Neoplasma
. 2023 Jan;
69(6):1466-1473.
PMID: 36591807
Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin's lymphoma with an aggressive course. To refine the individual patient's prognosis, the International Prognostic Index for BL (BL-IPI) was recently developed...
10.
Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, et al.
Ann Hematol
. 2022 Nov;
102(1):107-115.
PMID: 36369497
Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with...